Vladimir R. Muzykantov, MD, PhD
Founders Professor in Nanoparticle Research
Member, Institute of Medical Engineering, University of Pennsylvania School of Medicine
Member, Center for Cancer Pharmacology, University of Pennsylvania School of Medicine
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Member, Center for Environmental Toxicology, University of Pennsylvania School of Medicine
Member, Cardiovascular Institute, University of Pennsylvania School of Medicine
Vice-Chair for Faculty Development, Department of Pharmacology, University of Pennsylvania
Founding Co-Director of the PSOM/SEAS Center for Targeted Therapeutics and Translational Nanomedicine (CT3N) , University of Pennsylvania
Department: Systems Pharmacology and Translational Therapeutics
Graduate Group Affiliations
Contact information
10-105 Smilow Center for Translational Research
3400 Civic Center Blvd
Philadelphia, PA 19104-5158
3400 Civic Center Blvd
Philadelphia, PA 19104-5158
Office: 215-898-9823
Fax: 215-898-0868
Fax: 215-898-0868
Email:
muzykant@mail.med.upenn.edu
muzykant@mail.med.upenn.edu
Publications
Links
Search PubMed for articles
Pharmacological Sciences Graduate Group Faculty
Lab Website
Primary Work Website
Search PubMed for articles
Pharmacological Sciences Graduate Group Faculty
Lab Website
Primary Work Website
Education:
M.D. (Internal Medicine)
First School of Medicine, Moscow, Russia, 1980.
Ph.D. (Biochemistry)
National Cardiology Research Center, Moscow, Russia, 1985.
M.A. (Honoris Causa)
University of Pennsylvania, 2004.
Permanent linkM.D. (Internal Medicine)
First School of Medicine, Moscow, Russia, 1980.
Ph.D. (Biochemistry)
National Cardiology Research Center, Moscow, Russia, 1985.
M.A. (Honoris Causa)
University of Pennsylvania, 2004.
Description of CVI Expertise
CVI Program Unit(s):Biotechnology / Nanomedicine / Imaging
Thrombosis / Hemostasis
CVI Research Description:
Dr. Muzykantov focuses on targeted drug delivery to the endothelium and blood cells for treatment of thrombosis, ischemia and other cardiovascular maladies. He also teaches cardiovascular biology to graduate students in pharmacology.
Selected Publications
Reyes-Esteves S, Nong J, Glassman PM, Omo-Lamai S, Ohashi S, Myerson JW, Zamora ME, Ma X, Kasner SE, Sansing L, Muzykantov VR, Marcos-Contreras OA, Brenner JS.: Targeted drug delivery to the brain endothelium dominates over passive delivery via vascular leak in experimental intracerebral hemorrhage. J Control Release Mar 2023.Glassman PM, Villa CH, Marcos-Contreras OA, Hood ED, Walsh LR, Greineder CF, Myerson JW, Shuvaeva T, Puentes L, Brenner JS, Siegel DL, Muzykantov VR.: Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation. Bioconjug Chem. June 2022.
Parhiz H, Brenner JS, Patel PN, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora ME, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson JW, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov VR.: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). J Control Release(344), 50-61, Apr 2022.
Ferguson LT, Hood ED, Shuvaeva T, Shuvaev VV, Basil MC, Wang Z, Nong J, Ma X, Wu J, Myerson JW, Marcos-Contreras OA, Katzen J, Carl JM, Morrisey EE, Cantu E, Villa CH, Mitragotri S, Muzykantov VR, Brenner JS.: Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers. ACS Nano.(16), 4666-4683, Mar 2022.
Wang Z, Hood ED, Nong J, Ding J, Marcos-Contreras OA, Glassman PM, Rubey KM, Zaleski M, Espy CL, Gullipali D, Miwa T, Muzykantov VR, Song WC, Myerson JW, Brenner JS. : Combating complement's deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv Mater. Feb 2022.
Myerson JW, Patel PN, Rubey KM, Zamora ME, Zaleski MH, Habibi N, Walsh LR, Lee YW, Luther DC, Ferguson LT, Marcos-Contreras OA, Glassman PM, Mazaleuskaya LL, Johnston I, Hood ED, Shuvaeva T, Wu J, Zhang HY, Gregory JV, Kiseleva RY, Nong J, Grosser T, Greineder CF, Mitragotri S, Worthen GS, Rotello VM, Lahann J, Muzykantov VR, Brenner JS. : Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nanotechnol 17(1): 86-97, Jan 2022.
Parhiz H, Brenner JS, Patel P, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora M, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson J, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov V. : Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation(IE). J Control Release Dec 2021.
Tutwiler V, Litvinov RI, Protopopova A, Nagaswami C, Villa C, Woods E, Abdulmalik O, Siegel DL, Russell JE, Muzykantov VR, Lam WA, Myers DR, Weisel JW. : Pathologically stiff erythrocytes impede contraction of blood clots: Reply to comment. J Thromb Haemost. 19(11): 2894-2895, Nov 2021.
Nikfar M, Razizadeh M, Paul R, Muzykantov V, Liu Y.: A numerical study on drug delivery via multiscale synergy of cellular hitchhiking onto red blood cells. Nanoscale Sep 2021 Notes: doi: 10.1039/d1nr04057j. Epub ahead of print.
Tutwiler V, Litvinov RI, Protopopova A, Nagaswami C, Villa C, Woods E, Abdulmalik O, Siegel DL, Russell JE, Muzykantov VR, Lam WA, Myers DR, Weisel JW.: Pathologically stiff erythrocytes impede contraction of blood clots. J Thromb Haemost. July 2021 Notes: doi: 10.1111/jth.15407. Epub ahead of print.